BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ochnik AM, Baxter RC. Combination therapy approaches to target insulin-like growth factor receptor signaling in breast cancer. Endocr Relat Cancer 2016;23:R513-36. [PMID: 27733416 DOI: 10.1530/ERC-16-0218] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Duan L, Calhoun S, Perez RE, Macias V, Mir F, Pergande MR, Gattuso P, Borgia JA, Maki CG. Prolyl Carboxypeptidase Maintains Receptor Tyrosine Kinase Signaling and Is a Potential Therapeutic Target in Triple Negative Breast Cancer. Cancers (Basel) 2022;14:739. [PMID: 35159006 DOI: 10.3390/cancers14030739] [Reference Citation Analysis]
2 Ikeda Y, Yasutake R, Yuki R, Saito Y, Nakayama Y. Combination Treatment of OSI-906 with Aurora B Inhibitor Reduces Cell Viability via Cyclin B1 Degradation-Induced Mitotic Slippage. Int J Mol Sci 2021;22:5706. [PMID: 34071893 DOI: 10.3390/ijms22115706] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Monchusi B, Kaur M. microRNAs targeting cellular cholesterol: implications for combating anticancer drug resistance. Genes Cancer 2020;11:20-42. [PMID: 32577155 DOI: 10.18632/genesandcancer.202] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Sinai-Livne T, Pasmanik-Chor M, Cohen Z, Tsarfaty I, Werner H, Berger R. Proteomic analysis of combined IGF1 receptor targeted therapy and chemotherapy identifies signatures associated with survival in breast cancer patients. Oncotarget 2020;11:1515-30. [PMID: 32391121 DOI: 10.18632/oncotarget.27566] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Ortega MA, Fraile-Martínez O, Asúnsolo Á, Buján J, García-Honduvilla N, Coca S. Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTOR. J Oncol 2020;2020:9258396. [PMID: 32211045 DOI: 10.1155/2020/9258396] [Cited by in Crossref: 37] [Cited by in F6Publishing: 55] [Article Influence: 18.5] [Reference Citation Analysis]
6 Yamagishi A, Ikeda Y, Ikeuchi M, Yuki R, Saito Y, Nakayama Y. Targeting Insulin-Like Growth Factor 1 Receptor Delays M-Phase Progression and Synergizes with Aurora B Inhibition to Suppress Cell Proliferation. Int J Mol Sci 2020;21:E1058. [PMID: 32033461 DOI: 10.3390/ijms21031058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Manzella L, Massimino M, Stella S, Tirrò E, Pennisi MS, Martorana F, Motta G, Vitale SR, Puma A, Romano C, Di Gregorio S, Russo M, Malandrino P, Vigneri P. Activation of the IGF Axis in Thyroid Cancer: Implications for Tumorigenesis and Treatment. Int J Mol Sci 2019;20:E3258. [PMID: 31269742 DOI: 10.3390/ijms20133258] [Cited by in Crossref: 13] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
8 Pian L, Wen X, Kang L, Li Z, Nie Y, Du Z, Yu D, Zhou L, Jia L, Chen N, Li D, Zhang S, Li W, Hoffman AR, Sun J, Cui J, Hu JF. Targeting the IGF1R Pathway in Breast Cancer Using Antisense lncRNA-Mediated Promoter cis Competition. Mol Ther Nucleic Acids 2018;12:105-17. [PMID: 30195750 DOI: 10.1016/j.omtn.2018.04.013] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
9 Ochnik AM, Baxter RC. Insulin-like growth factor receptor and sphingosine kinase are prognostic and therapeutic targets in breast cancer. BMC Cancer 2017;17:820. [PMID: 29207959 DOI: 10.1186/s12885-017-3809-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]